American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Gynecology. ACOG Practice Bulletin No. 200: Early Pregnancy Loss. Obstet Gynecol. 2018;132(5):e197-e207. doi:10.1097/AOG.0000000000002899
American College of Obstetricians and Gynecologists. Improving access to mifepristone for reproductive health indications. Position Statement. Washington, DC: American College of Obstetricians and Gynecologists; 2018. (Level III)
Consensus Statement: Instructions for Us–Misoprostol for Treatment of Incomplete Abortion and Miscarriage. Expert Meeting on Misoprostol sponsored by Reproductive Health Technologies Project and Gynuity Health Projects. June 9, 2004. New York, NY.
Dzuba IG, Castillo PW, Bousiéguez M, Margarita Lugo Hernández E, Juan Castañeda Vivar J, Sanhueza Smith P. A repeat dose of misoprostol 800mcg following mifepristone for outpatient medical abortion at 64-70 and 71-77 days of gestation: A retrospective chart review [published online ahead of print, 2020 May 28]. Contraception. 2020;S0010-7824(20)30160-8.
Flink-Bochacki R, Hamm ME, Borrero S, Chen BA, Achilles SL, Chang JC. Family Planning and Counseling Desires of Women Who Have Experienced Miscarriage. Obstet Gynecol. 2018;131(4):625-631. doi:10.1097/AOG.0000000000002520
Flynn AN, Roe AH, Koelper N, McAllister A, Sammel MD, Schreiber CA. Timing and efficacy of mifepristone pretreatment for medical management of early pregnancy loss. Contraception. 2021;103(6):404-407. doi:10.1016/j.contraception.2021.01.007
Henkel A, Shaw KA. Advances in the management of early pregnancy loss. Curr Opin Obstet Gynecol. 2018;30(6):419-424. doi:10.1097/GCO.0000000000000501
Mark A, Foster AM, Grossman D, Prager SW, Reeves M, Velásquez CV, et al. Foregoing Rh testing and anti-D immunoglobulin for women presenting for early abortion: a recommendation from the National Abortion Federation’s Clinical Policies Committee. Contraception. 2019;99(5):265-66].
Nagendra D, Koelper N, Loza-Avalos SE, et al. Cost-effectiveness of Mifepristone Pretreatment for the Medical Management of Nonviable Early Pregnancy: Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2020;3(3):e201594. doi:10.1001/jamanetworkopen.2020.1594
The Practice Committee of the American Society for Reproductive Medicine. Evaluation and treatment of recurrent pregnancy loss: a committee opinion. Fertil Steril 2012;98:1103–11.
Roe AH, McAllister A, Sammel MD, Schreiber CA. Pregnancy intentions and contraceptive uptake after miscarriage. Contraception. 2020;101(6):427-431. doi:10.1016/j.contraception.2020.03.002
Schreiber CA, Creinin MD, Atrio J, Sonalkar S, Ratcliffe SJ, Barnhart KT. Mifepristone pretreatment for the medical management of early pregnancy loss. N Engl J Med 2018; 378:2161–70. (Level I)
Shorter JM, Atrio JM, Schreiber CA. Management of early pregnancy loss, with a focus on patient centered care. Semin Perinatol. 2019;43(2):84-94. doi:10.1053/j.semperi.2018.12.005
Wallace R, DiLaura A, Dehlendorf C. “ ‘Every person’s just different’: Women’s Experiences with Counseling for Early Pregnancy Loss Management.” Women’s Health Issues, 2017; 27-4: 456-462.
Wiebe E, Campbell M, Aiken A, Albert A. Can we safely stop testing for rh status and immunizing rh-negative women having early abortions? A comparison of Rh alloimmunization in Canada and the Netherlands. Contraception: X. 2019;100001;
Zhang J, Gilles JM, Barnhart K, Creinin MD, Westhoff C, Frederick MM. A comparison of medical management with misoprostol and surgical management for early pregnancy failure. National Institute of Child Health Human Development (NICHD) Management of Early Pregnancy Failure Trial. N Engl J Med 2005;353:761–9.